Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

Registration

Registration

NCT07354880

Acronym

TEACH

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE4

Masking

DOUBLE

Status

NOT_YET_RECRUITING

Enrollment

30

Start

2026-01-20

Primary completion

2027-06-30

Lead sponsor

University Medical Centre Ljubljana

Conditions

Obesity & Overweight; Adult Congenital Heart Disease

Interventions

DRUG:Treatment with tirzapatide; DRUG:Treatment with placebo

Results posted

FALSE

Individual participant data sharing

YES

Registered primary outcomes

• Change in exercise capacity after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).]
• Change in left ventricular systolic function after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).]
• Change in cholesterol levels after 6 months of treatment with tirzepatide. [From enrollment (visit 1) to the end of the treatment at 6 months (visit 6).]